MedPath

Fish Oil (Omega 3 ) in Sjogren's Syndrome

Phase 2
Completed
Conditions
Sjogren's Syndrome
Interventions
Drug: Omega 3 fatty acid
Drug: Placebo
Registration Number
NCT05005806
Lead Sponsor
Hawler Medical University
Brief Summary

Sjögren's syndrome (pSS) is an autoimmune disorder affecting mainly the exocrine glands.this lead to dryness of the main mucosal surface ,such as the mouth ,eye,skin nose,pharynx,larynx and vagina . The history of the disease is characterized by a slowly progression of sicca symptoms and fatigue; however, a subset of patients would experience extra glandular activity. Lipid mediators derived from polyunsaturated fatty acids, related to inflammation and immune response regulation. In this sense, the polyunsaturated fatty acids omega-3 (ω-3 FA) have been associated with several illnesses such as cancer, cardiovascular disease and autoimmune diseases and their balance at the cellular membranes can result in an anti-inflammatory .

Detailed Description

this is a randomized double -blind placebo -controlled clinical trial .the participants will be randomize into two groups .Group 1 receive dietary omega-3 supplementation (omega-3 group) whereas Group 2(placebo group) receive a placebo . The two types are similar to each other in the form of soft gel ,both are given two times daily for two months with follow-up of patients whom they full fill the inclusion criteria.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Age≥ 18 and ≤ 70 years old .
  • Able to provide inform consent
  • Patients diagnosed as syndrome according to 2016 ACR(American college of Rheumatology)/ EULAR(European league Against Rheumatism classification criteria for Sjögren's syndrome
Exclusion Criteria
  • any preexisting ocular disease or on eye drops lubricants.
  • patients on (Beta blockers, Diuretics , anticholinergic, α 1antagonist and α 2 agonist ,anticoagulant, antidepressant, antihistamine ,pilocarpine, cevimeline ) .
  • past history of diabetes, psychiatric disorder.
  • pregnancy, lactating mother
  • malignancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Omega 3 soft gelOmega 3 fatty acidparticipants in this group (1)omega 3 fatty acid soft gel 1000 mg will be given to participants twice daily for two months.
placeboPlaceboplacebo group ,placebo soft gel designed same as omega 3 contain Vitamin A 1000 mg twice daily for two months
Primary Outcome Measures
NameTimeMethod
Dry mouth symptomsup to two months

measure dry mouth by inventory xerostomia score is included 11 questionnaire which score calculated by visual analogue scale from 1 to 5 ( never to very often ) have symptoms

Dry eye symptomsup to two months

subjective symptoms of dry eye which involve 6 symptoms( burning sensation, itching, foreign body sensation , Dryness, mucous discharge, photophobia) when absent(0) , sometime present (1) , frequently present (2), always present (3) ( score 0-6 mild, 6-12 moderate, 12-18 sever by visual analogue scale

Secondary Outcome Measures
NameTimeMethod
sialometry testup to two months

measuring of salivary flow ,unstimulated whole saliva is collect when mouth rinse with distill water then the patient tow his head and try not to move during the test, a plastic disposable pipette drew the accumulated saliva in the floor of the mouth,for a period of five minute,the volume will record ,flow express as ml/min.

schirmers tear testup to two months

patient will sitt in examining chair ,the test strip is bend with round wick and at indentation ( approximately 90 degree ) then patient instruct to look up and draw eye gently downward ,then round bend end of sterile strip hook over eyelid border at junction of middle and outer one third of the lower eyelid margin.

Trial Locations

Locations (1)

Reumatology out patient clinic,

🇮🇶

Erbil, Iraq

© Copyright 2025. All Rights Reserved by MedPath